Oncaspar shortage — CH supply status & alternatives

Oncaspar

—

🇦🇺 AUST R 303807 · Servier Laboratories Australia Pty Ltd

In supply · Australia

Oncaspar Pulver zur Herstellung einer Injektionslösung

In supply · 🇦🇺 Australia · short in🇨🇭 CH

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Active ingredient (INN)	Oncaspar
Brand names	Oncaspar Pulver zur Herstellung einer Injektionslösung
Therapeutic category	Auto-created by Swissmedic scraper

Controlled substance	No

Marketing-authorisation holders	Servier Laboratories Australia Pty Ltd, Servier Pharmaceuticals LLC, Les Laboratoires Servier, SERVIER CANADA INC

Registrations on file	4

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Verified timeline regulator events

🇨🇭 5 July 2026

medium reported

🇨🇭 4 July 2026

medium reported

🇨🇭 1 July 2026

medium reported

🇨🇭 28 June 2026

medium reported

🇨🇭 27 June 2026

medium reported

🇨🇭 26 June 2026

medium reported

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders4 registrations · 4 MA holders

Product	Strength	Form	Market	MA holder	Status
ONCASPAR pegaspargase	3750 units	—	🇦🇺 AU	Servier Laboratories Australia Pty Ltd	Active
ONCASPAR	750[iU]/mL	injection	🇺🇸 US	Servier Pharmaceuticals LLC	Active
Oncaspar	—	—	🌐 EU	Les Laboratoires Servier	Active
ONCASPAR	—	solution	🇨🇦 CA	SERVIER CANADA INC	Active

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.